Brian Slomovitz, MD, MS, FACOG, discussed plans for future research of tisotumab vedotin. He presented updated findings from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial. At this point, we’re focusing on cervical cancer.
#WORLD #English #PL
Read more at Cancer Network